Pair page
Glumitide with Liraglutide
Mechanism-tag overlap and published literature for Glumitide and Liraglutide, pulled verbatim from each Kalios compound profile. Kalios is a literature reference, not a recommendation.
Mechanism overlap
Mechanism tags are verbatim labels on each compound's profile. Generic tags ("peptide", "small-molecule", "research-chemical") are excluded from this overlap view. Tags are descriptive — not an inference about combined effect.
selective-gip-receptor-agonist
incretin-peptide
daily-glp-1-receptor-agonist
Co-administration notes from the literature
Verbatim summary text pulled from each compound's profile data. Researchers studying Glumitide and Liraglutide have published these mechanism-level observations. Not a co-administration recommendation.
Knop et al., Diabetes Obes Metab 2024 (NCT05444569): single 25 mg SC LY3537021 followed by daily liraglutide dose-escalation (0.6 → 2.4 mg through day 9) in healthy volunteers reduced GI adverse-event burden — primarily nausea and vomiting — versus liraglutide alone. Diarrhea was unchanged. This is a Phase 1 mechanistic finding establishing the GI-tolerability hypothesis for selective GIPR agonism added to GLP-1R agonist therapy. Not a clinical-practice combination regimen.
Quick facts
Glumitide
Liraglutide
Literature table
Classified references from each compound profile. Click a column header to sort. Click a PMID to open PubMed. Findings are quoted verbatim from each profile's literature_summary; nothing here is added or interpreted.
| Year | Compound | Source | Finding |
|---|---|---|---|
| 2025 | Glumitide | Pratt EJ, Roell W, Knop FK, Urva S, et al. Long-acting GIPR agonist LY3537021 reduces body weight and fasting blood glucose in patients with T2D: Preclinical development and phase 1 randomized ascending dose studies. PMID: 41391569; PMC: PMC12808604. PMID 41391569 | |
| 2024 | Glumitide | Knop FK, Pratt EJ, Roell W, et al. A long-acting glucose-dependent insulinotropic polypeptide receptor agonist improves the gastrointestinal tolerability of glucagon-like peptide-1 receptor agonist therapy. Diabetes Obes Metab. 2024. DOI: 10.1111/dom.15875. (NCT05444569 — co-adm… PMID doi:10.1111/dom.15875 | |
| 2023 | Glumitide | Knop FK, Urva S, Rettiganti M, Benson C, Roell W, Mather KJ, Haupt A, Pratt EJ. 56-OR: A Long-Acting Glucose-Dependent Insulinotropic Polypeptide Receptor Agonist Shows Weight Loss without Nausea or Vomiting. Diabetes 2023;72(Supplement_1):56-OR. (ADA scientific session abstract… PMID doi:10.2337/db23-56-OR | |
| 2022 | Liraglutide | Rubino DM, Greenway FL, Khalid U, et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes (STEP 8). JAMA. 2022;327(2):138-150. PMID: 35015037. (Head-to-head sema vs lira.) PMID 35015037 | human trial |
| 2020 | Liraglutide | Kelly AS, Auerbach P, Barrientos-Perez M, Gies I, Hale PM, Marcus C, Mastrandrea LD, Prabhu N, Arslanian S; NN8022-4180 Trial Investigators. A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity. N Engl J Med. 2020;382(22):2117-2128. PMID: 32320651. PMID 32320651 | human trial |
| 2020 | Liraglutide | Verma S, Bain SC, Honoré JB, et al. Effects of Liraglutide on Cardiovascular Outcomes in Patients With Diabetes With or Without Heart Failure (LEADER substudy). J Am Coll Cardiol. 2020;75(13):1505-1517. PMID: 32164886. PMID 32164886 | human trial |
| 2017 | Liraglutide | Mann JFE, Ørsted DD, Brown-Frandsen K, Marso SP, Poulter NR, Rasmussen S, Tornøe K, Zinman B, Buse JB; LEADER Steering Committee and Investigators. Liraglutide and Renal Outcomes in Type 2 Diabetes. N Engl J Med. 2017;377(9):839-848. PMID: 28854085. PMID 28854085 | human trial |
| 2016 | Liraglutide | Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, Steinberg WM, Stockner M, Zinman B, Bergenstal RM, Buse JB; LEADER Steering Committee. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 201… PMID 27295427 | human trial |
| 2015 | Liraglutide | Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M, Lau DC, le Roux CW, Violante Ortiz R, Jensen CB, Wilding JP; SCALE Obesity and Prediabetes NN8022-1839 Study Group. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med. 2015… PMID 26132939 | human trial |
| 2015 | Liraglutide | Davies MJ, Bergenstal R, Bode B, Kushner RF, Lewin A, Skjøth TV, Andreasen AH, Jensen CB, DeFronzo RA; NN8022-1922 Study Group. Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial. JAMA. 2015;314(7):687-699. P… PMID 26284720 | human trial |
| 2013 | Liraglutide | Wadden TA, Hollander P, Klein S, et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study. Int J Obes (Lond). 2013;37(11):1443-1451. PMID: 23812094. PMID 23812094 | human trial |
| 2009 | Liraglutide | Astrup A, Rössner S, Van Gaal L, et al. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet. 2009;374(9701):1606-1616. PMID: 19853906. PMID 19853906 | human trial |
| — | Liraglutide | NICE. Liraglutide for the treatment of type 2 diabetes mellitus and weight management. UK National Institute for Health and Care Excellence guidance documents. | human study |
| 2014 | Liraglutide | FDA. Saxenda (liraglutide) prescribing information. December 2014, updated periodically. | regulatory / registry |
| 2010 | Liraglutide | FDA. Victoza (liraglutide) prescribing information. January 2010, updated periodically. | regulatory / registry |
Related pair pages
More research context
Frequently asked
Have Glumitide and Liraglutide been studied together?
Researchers have published mechanistic-level co-administration discussion of Glumitide and Liraglutide. No human co-administration trials are catalogued in the Kalios profiles. The pair page lists each compound's classified literature; full citations sit on each individual profile.
What mechanisms do Glumitide and Liraglutide share?
Glumitide and Liraglutide share these mechanism tags on their Kalios profiles: incretin-peptide. Tags are descriptive and verbatim from each compound profile — not an inference of combined effect.
What is the FDA status of Glumitide and Liraglutide?
Glumitide: Investigational New Drug (Phase 1). Liraglutide: Approved (T2D 2010, obesity 2014, peds 2019). FDA-status text is pulled verbatim from each compound profile. See /fda-pcac-2026.html for the broader FDA Pharmacy Compounding Advisory Committee context.
Where can I find the full research on Glumitide and Liraglutide?
Full citation lists, dosing tables from the literature, reconstitution data, and the FDA / WADA status are on the individual compound profiles: the Glumitide profile and the Liraglutide profile. The Kalios Stack Research Tool hub lists every compound covered.
Last updated: April 2026